Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury

Kidney International

Volumn 84, Issue 4, 2013, Pages 703-712

  Zager, Richard A ^a,b   Johnson, Ali C M ^b   Andress, Dennis ^c   Becker, Kirsten ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ABBVIE INC   (United States)

Author keywords

Atrasentan; BQ 788; endothelin 1; endothelin 1 receptor A; endothelin 1 receptor B; epigenetic modifications

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; HISTONE; KI 67 ANTIGEN; LACTIC ACID; MESSENGER RNA; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; RNA POLYMERASE II;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL PROTECTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME BINDING; ET 1 GENE; GENE; GENE ACTIVATION; HISTONE MODIFICATION; HISTOPATHOLOGY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUMOR; MALE; MICROVASCULAR INJURY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; TREATMENT DURATION; TREATMENT FAILURE; TUBULAR DYSFUNCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIN-1; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED STRAINS; OLIGOPEPTIDES; PIPERIDINES; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RENAL INSUFFICIENCY, CHRONIC; REPERFUSION INJURY; RNA, MESSENGER;

EID: 84885320788     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.157     Document Type: Article

References (44)

1. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
2. Xue JL, Daniels F, Star RA et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17: 1135-1142.
3. Waikar SS, Curhan GC, Wald R et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17: 1143-1150.
4. Liangos O, Wald R, O'Bell JW et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006; 1: 43-51.
5. Wald R, Quinn RR, Luo J et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009; 302: 1179-1185.
6. Goldberg A, Kogan E, Hammerman H et al. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int 2009; 76: 900-910.
7. Lo LJ, Go AS, Chertow GM et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 2009; 76: 893-899.
8. Basile DP, Friedrich JL, Spahic J et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol 2011; 300: F721-F733.
9. Basile DP, Leonard EC, Tonade D et al. Distinct effects on long-term function of injured and contralateral kidneys following unilateral renal ischemia-reperfusion. Am J Physiol Renal Physiol 2012; 302: F625-F635.
10. Leonard EC, Friedrich JL, Basile DP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol 2008; 295: F1648-F1657.
11. Pechman KR, De Miguel C, Lund H et al. Recovery from renal ischemiareperfusion injury is associated with altered renal hemodynamics, blunted pressure natriuresis, and sodium-sensitive hypertension. Am J Physiol 2009; 297: R1358-R1363.
12. Spurgeon-Pechman KR, Donohoe DL, Mattson DL et al. Recovery from acute renal failure predisposes hypertension and secondary renal disease in response to elevated sodium. Am J Physiol 2007; 293: F269-F278.
13. Finn WF, Chevalier RL. Recovery from postischemic acute renal failure in the rat. Kidney Int 1979; 16: 113-123.
14. Finn WF, Fernandez-Repollet E, Goldfarb D et al. Attenuation of injury due to unilateral renal ischemia: delayed effects of contralateral nephrectomy. J Lab Clin Med 1984; 103: 193-203.
15. Zager RA, Johnson AC, Becker K. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease. Am J Physiol 2011; 301: F1334-F1345.
16. Kawanabe Y, Nauli SM. Endothelin. Cell Molec Life Sci 2011; 68: 195-203.
17. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Therapeutics 2006; 110: 386-414.
18. Mino N, Kobayashi M, Nakajima A et al. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 1992; 221: 77-83.
19. Lopez-Farre A, Gomez-Garre D, Bernabeu F et al. A role for endothelin in the maintenance of post-ischaemic renal failure in the rat. J Physiol 1991; 444: 513-522.
20. Clozel M, Ramuz H, Clozel J-P et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmol Exp Ther 1999; 290: 840-846.
21. Arfian N, Emoto N, Vignon-Zellweger N-V et al. ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia-reperfusion injury. Biochem Biophys Res Commun 2012; 425: 443-449.
22. Abu-Saleh N, Ovcharenko E, Awad H et al. Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental diabetic model. Life Sci 2012; 91: 669-675.
23. Forbes JM, Hewitson TD, Becker GJ et al. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int 2001; 59: 1333-1341.
24. Forbes JM, Leaker B, Hewitson TD et al. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int 1999; 55: 198-208.
25. Fenhammar J, Andersson A, Forestier J et al. Endothelian receptor A antagonism attenuates renal medullary blood flow impairment in endotoxemic pigs. Plos 2011; 1: 6e21534.
26. Gellai M, Jugus M, Fletcher T et al. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J Clin Invest 1994; 93: 900-906.
27. Opgenorth TJ, Adler AL, Calzadilla SV et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276: 473-481.
28. Wessale JL, Adler AL, Novosad EI et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci 2002; Suppl 48: 112S-117S.
29. Naito M, Bomsztyk K, Zager RA. Endotoxin mediates recruitment of RNA polymerase II to target genes in acute renal failure. J Am Soc Nephrol 2008; 19: 1321-1330.
30. Naito M, Zager RA, Bomsztyk K. BRG1 increases transcription of proinflammatory genes in renal ischemia. J Am Soc Nephrol 2009; 20: 1787-1796.
31. Naito M, Bomsztyk K, Zager RA. Renal ischemia-induced cholesterol loading: transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene. Am J Pathol 2008; 174: 54-62.
32. Zager RA, Johnson AC. Progressive histone alterations and proinflammatory gene activation: consequences of heme protein/ironmediated proximal tubule injury. Am J Physiol 2010; 298: F827-F837.
33. Iwata M, Herrington J, Zager RA. Sphingosine: a mediator of acute renal tubular injury and subsequent cytoresistance. Proc Natl Acad Sci, USA 1995; 9: 8970-8974.
34. Iwata M, Herrington J, Zager RA. Protein synthesis inhibition induces cytoresistance in cultured human proximal tubular (HK-2) cells. Am J Physiol 1995; 268: F1154-F1163.
35. Nakano K, Watney E, McDougall JK. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am J Pathol 1998; 153: 857-864.
36. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003; 88: 163-166.
37. Nelson JB, Love W, Chin JL et al. Atrasentan Phase 3 Study Group. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-2487.
38. Zager RA, Johnson AC, Becker K. Post ischemic azotemia as a partial brake, slowing progressive renal disease. Nephrol Dialysis Transplant 2013 (in press).
39. Fakhouri F, Placier S, Ardaillou R et al. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 2001; 12: 2701-2710.
40. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543.
41. Cruz DN, Gaiao S, Maisel A et al. Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med 2012; 50: 1533-1545.
42. Khodorova A, Fareed MU, Gokin A et al. Local injection of a selective endothelin-B receptor antagonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner. J Neurosci 2002; 22: 788-796.
43. Webber KM, Pennefather JN, Head GA et al. Endothelin induces dopamine release from rat striatum via endothelin-B receptors. Neuroscience 1998; 86: 1173-1180.
44. Filippo CDi, Rossi F, Ongini E et al. The distinct alterations produced in cardiovascular functions by prednisolone and nitro-prednisolone (NCX-1015) in the rat highlight a cause role for endothelin-1. J Pharmacol Exp Therap 2004; 310: 1133-1141.